NCT00526708已完成不适用
RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 5,000
- 试验地点
- 1
研究概览
简要总结
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria
- •Over 18 years of age
- •Currently or previously diagnosed with hypertension and receiving medical care
排除标准
- •Patients already taking other hyperlipidemic agents
- •Patients who do not fulfil the indication criteria for statin therapy
- •Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)DiabetesDyslipidemiaNCT00526552AstraZeneca5,000
已完成
4 期
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic SyndromeMetabolic SyndromeNCT00815659AstraZeneca97
已完成
3 期
Crestor Versus Placebo in Subjects With Heart FailureHeart FailureNCT00206310AstraZeneca5,013
已完成
不适用
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia ControlCardiovascular DiseasesHyperlipidemiasNCT02913794Boryung Pharmaceutical Co., Ltd541
已完成
4 期
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic PatientsType IIa and IIb HypercholesterolaemiaNCT00631189AstraZeneca668